Icatibant Glenmark (Icatibant)

Icatibant is a selective antagonist of the bradykinin B2 receptor. By binding to this receptor, it blocks the action of bradykinin, a peptide that causes blood vessels to dilate and become more permeable, thereby preventing the fluid leakage that leads to swelling in hereditary angioedema.

The dose of Icatibant Glenmark is determined by the prescribing healthcare professional based on the patient’s condition, severity of the attack, and clinical guidelines. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

The safety of Icatibant during pregnancy and lactation has not been established. Healthcare providers will weigh the potential benefits against any possible risks before prescribing it to pregnant or nursing individuals.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved therapies such as C1‑esterase inhibitors replace a deficient protein, and newer monoclonal antibodies target different pathways. Icatibant offers a subcutaneous, rapid‑acting option that directly blocks bradykinin, making it useful for patients who prefer self‑administration during attacks.

The product should be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period.

Icatibant Glenmark is supplied as a sterile solution for subcutaneous injection. The patient or a trained caregiver injects the dose into the subcutaneous tissue, typically in the abdomen or thigh, using the pre‑filled syringe provided. Injection technique and site rotation are explained by the prescribing clinician.

Serious risks include anaphylaxis, airway angioedema that can compromise breathing, severe hypotension, and rare hematologic abnormalities such as thrombocytopenia. Patients should be monitored after injection, and any signs of severe allergic reaction or breathing difficulty require immediate medical attention.

Icatibant Glenmark should not be used by individuals with known hypersensitivity to icatibant or any of its excipients. It is also contraindicated in patients who have experienced severe allergic reactions to related bradykinin B2 antagonists. Clinical judgment is required for patients with unstable cardiovascular conditions.